KPS life WP
Acelyrin claims errors by CRO Fortrea after late-stage failure
A Phase IIb/III trial studying the company’s immunotherapy izokibep, failed to achieve statistical significance for its primary endpoint
Micron Biomedical receives funds to produce needle-free vaccines
AxoSim acquires microBrain technology to build neurological drug pipeline
Signal: LimmaTech raises $37m for antimicrobial resistance research
Novartis eyes accelerated FDA approval for iptacopan across multiple indications
FDA to start review of subcutaneous Entyvio for Crohn’s disease
